Switzerland-based Novartis announced on Monday that it has received the United States Food and Drug Administration (FDA)approval for the supplemental Biologics License Application for its Xolair (omalizumab) prefilled syringe for self-injection in appropriate patients across all approved US indications.
The product is claimed to be the only US FDA-approved biologic aimed at targeting and blocking immunoglobulin E (IgE) for the treatment of moderate to severe persistent allergic asthma, chronic idiopathic urticaria (CIU) and nasal polyps.
Novartis Pharmaceuticals Corporation and Genentech, a member of the Roche Group, collaborated to develop and co-promote the product in the United States.
AbbVie's ELAHERE receives full US FDA approval
Johnson & Johnson's OPSYNVI receives US FDA approval
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT